Accès gratuit
Méd. Intensive Réa.
Volume 26, Numéro 2, Mars 2017
Page(s) 111 - 122
Section Mise au point / Update
Publié en ligne 6 février 2017
  • Levy B, Bastien O, Bendjelid K, Cariou A, Chouihed T, Combes A, Mebazaa A, Megarbane B, Plaisance P, Ouattara A, Spaulding C, Teboul JL, Vanhuyse F, Boulain T, Kuteifan K, (2015) Experts’ recommendations for the management of adult patients with cardiogenic shock. Ann Intensive Care 5: 52 [Google Scholar]
  • Dar O, Cowie MR, (2008) Acute heart failure in the intensive care unit: epidemiology. Crit Care Med 36: S3–S8 [CrossRef] [PubMed] [Google Scholar]
  • Thiele H, Ohman EM, Desch S, Eitel I, de Waha S, (2015) Management of cardiogenic shock. Eur Heart J 36: 1223–1230 [CrossRef] [PubMed] [Google Scholar]
  • Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer JC, Erne P, Urban P, AMIS Plus Registry Investigators, (2008) Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med 149: 618–626 [CrossRef] [PubMed] [Google Scholar]
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37: 2129–2200 [CrossRef] [PubMed] [Google Scholar]
  • Starling EH, (1918) The Linacre lecture on the law of the heart. Longmans, Green and Co. London, UK [Google Scholar]
  • Klabunde RE, (2012) Cardiovascular physiology concepts, 2nd ed. Lippincott Williams & Wilkins/Wolters Kluwer, Philadelphia, PA [Google Scholar]
  • Pepine CJ, Nichols WW, Curry RC, Conti CR, (1979) Aortic input impedance during nitroprusside infusion. A reconsideration of afterload reduction and beneficial action. J Clin Invest 64: 643–654 [Google Scholar]
  • Merillon JP, Fontenier G, Lerallut JF, Jaffrin MY, Chastre J, Assayag P, Motte G, Gourgon R, (1984) Aortic input impedance in heart failure: comparison with normal subjects and its changes during vasodilator therapy. Eur Heart J 5: 447–455 [CrossRef] [PubMed] [Google Scholar]
  • Hochman JS, (2003) Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 107: 2998–3002 [CrossRef] [PubMed] [Google Scholar]
  • Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N, McLean A, Vilas-Boas F, Mebazaa A, (2011) Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 37: 619–626 [CrossRef] [PubMed] [Google Scholar]
  • Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J, 3CPO Trialists, (2008) Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med 359: 142–151 [CrossRef] [PubMed] [Google Scholar]
  • Naughton MT, Rahman MA, Hara K, Floras JS, Bradley TD, (1995) Effect of continuous positive airway pressure on intrathoracic and left ventricular transmural pressures in patients with congestive heart failure. Circulation 91: 1725–1731 [CrossRef] [PubMed] [Google Scholar]
  • Lenique F, Habis M, Lofaso F, Dubois-Randé JL, Harf A, Brochard L, (1997) Ventilatory and hemodynamic effects of continuous positive airway pressure in left heart failure. Am J Respir Crit Care Med 155: 500–505 [CrossRef] [PubMed] [Google Scholar]
  • Samii K, Fourcade O, Geeraerts T, Minville V, (2014) Traité d’anesthésie et de réanimation. Médecine-Sciences, Paris [Google Scholar]
  • Funk DJ, Jacobsohn E, Kumar A, (2013) The role of venous return in critical illness and shock — Part I: physiology. Crit Care Med 41: 250–257 [Google Scholar]
  • Funk DJ, Jacobsohn E, Kumar A, (2013) Role of the venous return in critical illness and shock— Part II: shock and mechanical ventilation. Crit Care Med 41: 573–579 [CrossRef] [PubMed] [Google Scholar]
  • Nozawa T, Cheng CP, Noda T, Little WC, (1994) Relation between left ventricular oxygen consumption and pressure-volume area in conscious dogs. Circulation 89: 810–817 [CrossRef] [PubMed] [Google Scholar]
  • Müller S, How OJ, Jakobsen Ø, Hermansen SE, Røsner A, Stenberg TA, Myrmel T, (2010) Oxygen-wasting effect of inotropy: is there a need for a new evaluation? An experimental large-animal study using dobutamine and levosimendan. Circ Heart Fail 3: 277–285 [Google Scholar]
  • O’Connor CM, Gattis WA, Uretsky BF, Adams KF, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM, (1999) Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138: 78–86 [CrossRef] [PubMed] [Google Scholar]
  • Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, Young JB, Rayburn BK, Rogers JG, DeMarco T, Leier CV, (2007) Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 153: 98–104 [CrossRef] [PubMed] [Google Scholar]
  • Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, Delgado JF, Follath F, (2011) Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 37: 290–301 [CrossRef] [PubMed] [Google Scholar]
  • Tacon CL, McCaffrey J, Delaney A, (2012) Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med 38: 359–367 [CrossRef] [PubMed] [Google Scholar]
  • Cleland JGF, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP, (2004) Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 6: 501–508 [CrossRef] [PubMed] [Google Scholar]
  • Gallet R, Ternacle J, Damy T, Guendouz S, Bremont C, Seemann A, Gueret P, Dubois-Rande JL, Lim P, (2014) Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction. Int J Cardiol 176: 450–455 [Google Scholar]
  • Smithies M, Yee TH, Jackson L, Beale R, Bihari D, (1994) Protecting the gut and the liver in the critically ill: effects of dopexamine. Crit Care Med 22: 789–795 [CrossRef] [PubMed] [Google Scholar]
  • Levy B, Nace L, Bollaert PE, Dousset B, Mallie JP, Larcan A, (1999) Comparison of systemic and regional effects of dobutamine and dopexamine in norepinephrine-treated septic shock. Intensive Care Med 25: 942–948 [CrossRef] [PubMed] [Google Scholar]
  • Kiefer P, Tugtekin I, Wiedeck H, Bracht H, Geldner G, Georgieff M, Radermacher P, (2000) Effect of a dopexamine-induced increase in cardiac index on splanchnic hemodynamics in septic shock. Am J Respir Crit Care Med 161: 775–779 [CrossRef] [PubMed] [Google Scholar]
  • Schmoelz M, Schelling G, Dunker M, Irlbeck M, (2006) Comparison of systemic and renal effects of dopexamine and dopamine in norepinephrine-treated septic shock. J Cardiothorac Vasc Anesth 20: 173–178 [CrossRef] [PubMed] [Google Scholar]
  • Yamani MH, Haji SA, Starling RC, Kelly L, Albert N, Knack DL, Young JB, (2001) Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact. Am Heart J 142: 998–1002 [CrossRef] [PubMed] [Google Scholar]
  • Petersen JW, Felker GM, (2008) Inotropes in the management of acute heart failure. Crit Care Med 36: S106–S111 [CrossRef] [PubMed] [Google Scholar]
  • Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS, Massie BM, O’Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M, Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators, (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287: 1541–1547 [CrossRef] [PubMed] [Google Scholar]
  • Earl GL, Fitzpatrick JT, (2005) Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure. Ann Pharmacother 39: 1888–1896 [CrossRef] [PubMed] [Google Scholar]
  • Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N, (1997) Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 333: 249–259 [CrossRef] [PubMed] [Google Scholar]
  • Nieminen MS, Buerke M, Cohen-Solál A, Costa S, Édes I, Erlikh A, Franco F, Gibson C, Gorjup V, Guarracino F, Gustafsson F, Harjola VP, Husebye T, Karason K, Katsytadze I, Kaul S, Kivikko M, Marenzi G, Masip J, Matskeplishvili S, Mebazaa A, Møller JE, Nessler J, Nessler B, Ntalianis A, Oliva F, Pichler-Cetin E, Põder P, Recio-Mayoral A, Rex S, Rokyta R, Strasser RH, Zima E, Pollesello P, (2016) The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion. Int J Cardiol 218: 150–157 [Google Scholar]
  • Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, Foster E, Chatterjee K, (2005) Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 111: 1504–1509 [CrossRef] [PubMed] [Google Scholar]
  • Follath F, Cleland JGF, Just H, Papp JGY, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, others, (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. The Lancet 360: 196–202 [CrossRef] [PubMed] [Google Scholar]
  • Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI, RUSSLAN Study Investigators, (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23: 1422–1432 [CrossRef] [PubMed] [Google Scholar]
  • Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M, SURVIVE Investigators, (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297: 1883–1891 [CrossRef] [PubMed] [Google Scholar]
  • Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Söffker G, Lemm H, Swyter M, Wegener N, Winkler M, Carter JM, Reith S, Werdan K, Buerke M, (2007) Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 35: 2732–2739 [CrossRef] [PubMed] [Google Scholar]
  • Samimi-Fard S, García-González MJ, Domínguez-Rodríguez A, Abreu-González P, (2008) Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol 127: 284–287 [Google Scholar]
  • Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T, REVIVE Heart Failure Study Group, (2013) Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 1: 103–111 [Google Scholar]
  • Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T, Weinbrenner C, Strasser RH, (2008) Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 36: 2257–2266 [CrossRef] [PubMed] [Google Scholar]
  • Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, Padley RJ, Huang B, Cohen-Solal A, (2009) Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 11: 304–311 [CrossRef] [PubMed] [Google Scholar]
  • Capomolla S, Pozzoli M, Opasich C, Febo O, Riccardi G, Salvucci F, Maestri R, Sisti M, Cobelli F, Tavazzi L, (1997) Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function. Am Heart J 134: 1089–1098 [CrossRef] [PubMed] [Google Scholar]
  • De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL, (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362: 779–789 [CrossRef] [PubMed] [Google Scholar]
  • Tarvasmäki T, Lassus J, Varpula M, Sionis A, Sund R, Køber L, Spinar J, Parissis J, Banaszewski M, Silva Cardoso J, Carubelli V, Di Somma S, Mebazaa A, Harjola VP, for the CardShock study investigators, (2016) Current real-life use of vasopressors and inotropes in cardiogenic shock — adrenaline use is associated with excess organ injury and mortality. Crit Care 20:208 [CrossRef] [PubMed] [Google Scholar]
  • Nativi-Nicolau J, Selzman CH, Fang JC, Stehlik J, (2014) Pharmacologic therapies for acute cardiogenic shock. Curr Opin Cardiol 29: 250–257 [CrossRef] [PubMed] [Google Scholar]
  • Levy B, Perez P, Perny J, Thivilier C, Gerard A, (2011) Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 39: 450–455 [CrossRef] [PubMed] [Google Scholar]
  • Pirracchio R, Parenica J, Resche Rigon M, Chevret S, Spinar J, Jarkovsky J, Zannad F, Alla F, Mebazaa A, for the GREAT network, (2013) The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis. PLoS One 8: e71659 [Google Scholar]
  • Zannad F, Mebazaa A, Juillière Y, Cohen-Solal A, Guize L, Alla F, Rougé P, Blin P, Barlet M-H, Paolozzi L, Vincent C, Desnos M, Samii K, EFICA Investigators, (2006) Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study. Eur J Heart Fail 8: 697–705 [CrossRef] [PubMed] [Google Scholar]
  • Spinar J, Parenica J, Vitovec J, Widimsky P, Linhart A, Fedorco M, Malek F, Cihalik C, Spinarová L, Miklik R, Felsoci M, Bambuch M, Dusek L, Jarkovsky J, (2011) Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Crit Care Lond Engl 15: R291 [CrossRef] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.